LEarning biOchemical Prostate cAncer Reccurance from histopathology sliDes (LEOPARD)
Creators: name: Faryna, Khrystyna
name: Grisi, Clement
name: Augusti, Vittorio
name: Bogaerts, Joep
name: Kammerer Jaquet, Solen-Florence
name: Allaume, Pierre
name: van der Laak, Jeroen
name: Litjens, Geert
Publisher: name: Zenodo
Year: 2024
Subjects: prostate cancer
biochemical recurrence
cancer survival
MICCAI 2024 challenges

description: Prostate cancer, impacting 1.4 million men annually, is a prevalent malignancy [1]. A substantial number of these individuals undergo prostatectomy as the primary curative treatment. The efficacy of this surgery is assessed, in part, by monitoring the concentration of prostate-specific antigen (PSA) in the bloodstream. While the role of PSA in prostate cancer screening is debatable [2,3], it serves as a valuable biomarker for postprostatectomy follow-up in patients. Following successful surgery, PSA concentration is typically undetectable (<0.1 ng/mL) within 4–6 weeks [4]. However, approximately 30% of patients experience biochemical recurrence, signifying the resurgence of prostate cancer cells. This recurrence serves as a prognostic indicator for progression to clinical metastases and eventual prostate cancer-related mortality [5,6,7,8].  Current clinical practices gauge the risk of biochemical recurrence by considering the International Society of Urological Pathology (ISUP) grade, PSA value at diagnosis, and TNM staging criteria [9]. A recent European consensus guideline suggests categorizing patients into low-risk, intermediate-risk, and high-risk groups based on these factors [10]. Notably, a high ISUP grade independently assigns a patient to the intermediate (grade 2/3) or high-risk group (grade 4/5).  The Gleason growth patterns, representing morphological patterns of prostate cancer, are used to categorize cancerous tissue into ISUP grade groups [11,12,13,14]. However, the ISUP grade has limitations, such as grading disagreement among pathologisdts[14] and coarse descriptors of tissue morphology.  Hypothesizing that artificial intelligence, specifically deep learning, could uncover finer morphological features' prognostic value, we are organizing the LEarning biOchemical Prostate cAncer Reccurance from histopathology sliDes (LEOPARD ) challenge. The goal of this challenge is to yield top-performance deep learning solution to predict the likelihood of early biochemical recurrence from H&E-stained histopathological tissue sections, i.e based on morphological features. 

REFERENCES1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https://doi.org/10.3322/caac.21660 (2021). 2. Grossman, D. C. et al. Screening for Prostate Cancer: US preventive services task force recommendation statement. JAMA 319, 1901–1913 (2018). 3. Heijnsdijk, E. A. M. et al. Summary statement on screening for prostate cancer in Europe. Int J Cancer 142, 741–746 (2018). 4. Goonewardene, S. S., Phull, J. S., Bahl, A. & Persad, R. A. Interpretation of PSA levels after radical therapy for prostate cancer. Trends Urol. Men S Health 5, 30–34 (2014). 5. Amling, C. L. et al. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 164, 101–105 (2000). 6. Freedland, S. J. et al. Risk of prostate cancer–specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294, 433–439 (2005). 7. Han, M., Partin, A. W., Pound, C. R., Epstein, J. I. & Walsh, P. C. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Ur. Clin. North Am. 28, 555–565 (2001). 8. Van den Broeck, T. et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur. Urol. 75, 967–87. (2019). 9. Epstein, J. I. et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 40, 244–252 (2016). 10. Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 79, 243–62. (2021). 11. Epstein, J. I. An update of the Gleason grading system. J. Urol. 183, 433–440 (2010). 12. Pierorazio, P. M., Walsh, P. C., Partin, A. W. & Epstein, J. I. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 111, 753–60. (2013). 13. Epstein, J. I. et al. A Contemporary Prostate Cancer Grading System: a validated alternative to the Gleason score. Eur. Urol. 69, 428–35. (2016). 14. van Leenders, G. J. L. H. et al. The 2019 International Society of Urological Pathology (ISUP) consensus conference on Grading of prostatic carcinoma. Am. J. Surg. Pathol. 44, e87–e99 (2020).